Analyst consensus rating
GeneDx Holdings Analyst Rating: none
Direct answer
GeneDx Holdings's consensus rating is none.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $90.44.
Forecast evidence checked September 7, 2026.
Get free GeneDx Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $85.99
- Average price target
- $90.44
- High price target
- $103.00
- Low price target
- $74.00
- Low target gap
- -13.9%
- Target upside
- +5.2%
- High target gap
- +19.8%
- Target range width
- 33.7%
- Consensus rating
- none
- Analysts
- 9
- Evidence date
- September 7, 2026
- Valid through
- September 14, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for GeneDx Holdings?
GeneDx Holdings has a verified none consensus. The same dataset has an average price target of $90.44.
How far are GeneDx Holdings's low and high targets from the recorded price?
The low target implies -13.9%, while the high target implies +19.8%.
How many analysts are included in GeneDx Holdings's consensus?
The verified consensus includes 9 analysts.
How is GeneDx Holdings's target upside or downside calculated?
The average target of $90.44 is divided by the recorded price of $85.99, then one is subtracted to produce +5.2%. This does not guarantee a future return.
When was GeneDx Holdings's analyst forecast verified?
The data was verified on 2026-09-07. The dataset is valid through 2026-09-14.